CN115323067B - 用于预测阴沟肠杆菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 - Google Patents
用于预测阴沟肠杆菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 Download PDFInfo
- Publication number
- CN115323067B CN115323067B CN202211133701.3A CN202211133701A CN115323067B CN 115323067 B CN115323067 B CN 115323067B CN 202211133701 A CN202211133701 A CN 202211133701A CN 115323067 B CN115323067 B CN 115323067B
- Authority
- CN
- China
- Prior art keywords
- drug
- enterobacter cloacae
- phenotype
- characteristic
- kpc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 82
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 229940079593 drug Drugs 0.000 title claims abstract description 71
- 241000588697 Enterobacter cloacae Species 0.000 title claims abstract description 57
- 230000035945 sensitivity Effects 0.000 title claims abstract description 32
- 238000012163 sequencing technique Methods 0.000 title abstract description 12
- 230000003115 biocidal effect Effects 0.000 title description 10
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960002182 imipenem Drugs 0.000 claims abstract description 15
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims abstract description 15
- 229960002260 meropenem Drugs 0.000 claims abstract description 13
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims description 47
- 101100026178 Caenorhabditis elegans egl-3 gene Proteins 0.000 claims description 8
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 claims description 8
- 101100108294 Caenorhabditis elegans aex-5 gene Proteins 0.000 claims description 7
- 101100058532 Caenorhabditis elegans bli-4 gene Proteins 0.000 claims description 7
- 101100187206 Enterobacter cloacae nmcR gene Proteins 0.000 claims description 7
- 101000702393 Homo sapiens Signal peptide peptidase-like 2B Proteins 0.000 claims description 5
- 102100030404 Signal peptide peptidase-like 2B Human genes 0.000 claims description 5
- 108010009816 IMP-8 enzyme Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000035772 mutation Effects 0.000 abstract description 21
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract description 16
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 abstract description 12
- 239000003242 anti bacterial agent Substances 0.000 abstract description 12
- 229940088710 antibiotic agent Drugs 0.000 abstract description 12
- 229960003376 levofloxacin Drugs 0.000 abstract description 12
- 229960003405 ciprofloxacin Drugs 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 206010059866 Drug resistance Diseases 0.000 description 24
- 238000000034 method Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 6
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 6
- -1 KPC-6 Proteins 0.000 description 5
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 101100111650 Enterobacter cloacae nmcA gene Proteins 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 238000004902 predicting drug resistance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211133701.3A CN115323067B (zh) | 2022-09-19 | 2022-09-19 | 用于预测阴沟肠杆菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211133701.3A CN115323067B (zh) | 2022-09-19 | 2022-09-19 | 用于预测阴沟肠杆菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115323067A CN115323067A (zh) | 2022-11-11 |
CN115323067B true CN115323067B (zh) | 2023-11-17 |
Family
ID=83930968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211133701.3A Active CN115323067B (zh) | 2022-09-19 | 2022-09-19 | 用于预测阴沟肠杆菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115323067B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104560981A (zh) * | 2015-01-23 | 2015-04-29 | 杭州迪安医学检验中心有限公司 | 一种检测细菌喹诺酮类耐药基因的引物及试剂盒 |
CN114067912A (zh) * | 2021-11-23 | 2022-02-18 | 天津金匙医学科技有限公司 | 基于机器学习筛选细菌耐药表型相关重要特征基因的方法 |
CN114333987A (zh) * | 2021-12-30 | 2022-04-12 | 天津金匙医学科技有限公司 | 一种基于宏基因组测序的预测耐药表型的数据分析方法 |
-
2022
- 2022-09-19 CN CN202211133701.3A patent/CN115323067B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104560981A (zh) * | 2015-01-23 | 2015-04-29 | 杭州迪安医学检验中心有限公司 | 一种检测细菌喹诺酮类耐药基因的引物及试剂盒 |
CN114067912A (zh) * | 2021-11-23 | 2022-02-18 | 天津金匙医学科技有限公司 | 基于机器学习筛选细菌耐药表型相关重要特征基因的方法 |
CN114333987A (zh) * | 2021-12-30 | 2022-04-12 | 天津金匙医学科技有限公司 | 一种基于宏基因组测序的预测耐药表型的数据分析方法 |
Non-Patent Citations (4)
Title |
---|
Deborah S. Ashcraft 等.1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST.Open Forum Infect Dis.2021,第8卷(第Suppl 1期),S735. * |
Negin Bolourchi等.Comparative resistome and virulome analysis of clinical NDM-1–producing carbapenem-resistant Enterobacter cloacae complex.Journal of Global Antimicrobial Resistance.2022,第28卷254–263. * |
冯婷婷等.阴沟肠杆菌感染与耐药机制的研究进展.中国人兽共患病学报.2017,第33卷(第10期),933-937. * |
王华等.2株产IMP型碳青霉烯酶阴沟肠杆菌的耐药特点及全基因组测序分析.临床与病理杂志.2022,第42卷(第6期),1275-1283. * |
Also Published As
Publication number | Publication date |
---|---|
CN115323067A (zh) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Olm et al. | inStrain profiles population microdiversity from metagenomic data and sensitively detects shared microbial strains | |
Ellington et al. | The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee | |
Hashem et al. | Biofilm formation in enterococci: genotype-phenotype correlations and inhibition by vancomycin | |
Lieberman et al. | Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures | |
Gibreel et al. | High metabolic potential may contribute to the success of ST131 uropathogenic Escherichia coli | |
Nwaiwu et al. | An in silico analysis of acquired antimicrobial resistance genes in Aeromonas plasmids | |
CN114898808B (zh) | 一种预测肺炎克雷伯菌对头孢吡肟敏感性的方法及系统 | |
Salamzade et al. | Inter-species geographic signatures for tracing horizontal gene transfer and long-term persistence of carbapenem resistance | |
Boeck et al. | Mycobacterium abscessus pathogenesis identified by phenogenomic analyses | |
Tchesnokova et al. | A novel 7-single nucleotide polymorphism-based clonotyping test allows rapid prediction of antimicrobial susceptibility of extraintestinal Escherichia coli directly from urine specimens | |
Lepuschitz et al. | Analytical performance validation of next-generation sequencing based clinical microbiology assays using a K-mer analysis workflow | |
WO2017012660A1 (en) | Genetic testing for predicting resistance of serratia species against antimicrobial agents | |
Hayer et al. | Global Distribution of Extended Spectrum Cephalosporin and Carbapenem Resistance and Associated Resistance Markers in Escherichia coli of Swine Origin–A Systematic Review and Meta-Analysis | |
Wang et al. | High prevalence of unstable antibiotic heteroresistance in cyanobacteria causes resistance underestimation | |
Lou et al. | Using strain-resolved analysis to identify contamination in metagenomics data | |
Rad et al. | Detection of NDM-1 producing Klebsiella pneumoniae ST15 and ST147 in Iran during 2019–2020 | |
Zhao et al. | Whole-genome sequencing reveals high-risk clones of Pseudomonas aeruginosa in Guangdong, China | |
Humphries et al. | Machine-learning model for prediction of cefepime susceptibility in Escherichia coli from whole-genome sequencing data | |
CN115651990B (zh) | 用于预测大肠埃希菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 | |
Liu et al. | Molecular epidemiology and clinical characteristics of the type VI secretion system in Klebsiella pneumoniae causing abscesses | |
Liu et al. | Three novel sequence types carbapenem-resistant Klebsiella pneumoniae strains ST5365, ST5587, ST5647 isolated from two tertiary teaching general hospitals in Shanxi Province, in North China: molecular characteristics, resistance and virulence factors | |
CN115305292B (zh) | 用于预测金黄色葡萄球菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 | |
CN115323067B (zh) | 用于预测阴沟肠杆菌对抗生素药敏表型的特征基因组合、试剂盒及测序方法 | |
Chilam et al. | Genomic surveillance of Pseudomonas aeruginosa in the Philippines, 2013–2014 | |
Adjei et al. | Phylogenetic analysis of carbapenem-resistant Acinetobacter baumannii isolated from different sources using Multilocus Sequence Typing Scheme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 100071 Room 110, 1st Floor, Building 3, No. 2, Dongbinhe Road, You'anmenwai, Fengtai District, Beijing Patentee after: Beijing Jinshao Medical Laboratory Co.,Ltd. Country or region after: China Patentee after: Tianjin JinKe Medical Technology Co.,Ltd. Patentee after: Tianjin Huazhinuo Technology Co.,Ltd. Address before: 100071 Room 110, 1st Floor, Building 3, No. 2, Dongbinhe Road, You'anmenwai, Fengtai District, Beijing Patentee before: Beijing Jinshao Medical Laboratory Co.,Ltd. Country or region before: China Patentee before: Tianjin JinKe Medical Technology Co.,Ltd. Patentee before: Jinshi Zhizao (Tianjin) Medical Technology Co.,Ltd. |